AVITA Medical, Inc. (ASX:AVH)

Market Cap	300.64M
Revenue (ttm)	114.90M
Net Income (ttm)	-91.47M
Shares Out	n/a
EPS (ttm)	-3.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	286,323
Average Volume	307,276
Open	2.330
Previous Close	2.300
Day's Range	2.285 - 2.340
52-Week Range	2.285 - 4.520
Beta	1.74
RSI	31.82
Earnings Date	May 8, 2025

About AVITA Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2020
• Employees: 260
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AVH

Financial Performance

In 2024, AVITA Medical's revenue was $64.25 million, an increase of 28.14% compared to the previous year's $50.14 million. Losses were -$61.85 million, 74.8% more than in 2023.

Financial numbers in USD